Related Experiment Videos
Pycnogenol may alleviate adverse effects in oncologic treatment
G Belcaro1, M R Cesarone, D Genovesi
1Vascular Labs and Physiology, Department of Biomedical Sciences, Gabriele D'Annunzio University, Chieti-Pescara, Chieti, Italy. cardres@abol.it
Panminerva Medica
|October 18, 2008
Summary
French maritime pine bark extract Pycnogenol supplementation may alleviate chemotherapy and radiotherapy side effects. This pilot study observed reduced nausea, vomiting, and fatigue in patients receiving Pycnogenol compared to placebo.
Area of Science:
- Oncology
- Pharmacology
- Nutraceuticals
Background:
- Chemotherapy and radiotherapy often cause significant adverse reactions.
- Targeted medications exist for individual side effects.
- French maritime pine bark extract (Pycnogenol) is a potential supplement for managing treatment side effects.
Purpose of the Study:
- To investigate the efficacy of Pycnogenol supplementation in alleviating chemotherapy and radiotherapy-induced side effects.
- To assess the impact of Pycnogenol on patients' quality of life during cancer treatment.
Main Methods:
- A pilot trial involving cancer patients undergoing their first cycle of chemotherapy or radiotherapy.
- Patients were divided into two groups: one received 150 mg Pycnogenol, the other a placebo.
- Side effects were monitored and severity assessed using a semi-quantitative visual analogue scale over two months.
Main Results:
- Pycnogenol group showed decreased frequency and severity of side effects compared to placebo.
- Significant improvements noted in oral mucositis, dry mouth/eyes, nausea, vomiting, diarrhea, edema, and weakness.
- Reduced incidence of venous thromboembolism and lower requirement for supportive medications and hospitalization.
Conclusions:
- Pycnogenol supplementation shows promise in reducing adverse effects of chemotherapy and radiotherapy.
- Further large-scale prospective studies are warranted to confirm benefits across different malignancies and treatment regimens.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...